- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02255461
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Study Overview
Status
Conditions
- Recurrent Childhood Medulloblastoma
- Childhood Choroid Plexus Tumor
- Childhood Ependymoblastoma
- Childhood Grade III Meningioma
- Childhood High-grade Cerebellar Astrocytoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Medulloepithelioma
- Recurrent Childhood Anaplastic Astrocytoma
- Recurrent Childhood Anaplastic Oligoastrocytoma
- Recurrent Childhood Anaplastic Oligodendroglioma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Giant Cell Glioblastoma
- Recurrent Childhood Glioblastoma
- Recurrent Childhood Gliomatosis Cerebri
- Recurrent Childhood Gliosarcoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD)/phase II recommended dose and describe toxicities related to PD-0332991 (palbociclib isethionate) in children with retinoblastoma protein 1 (Rb1) positive recurrent, progressive or refractory primary central nervous system (CNS) tumors.
II. To determine plasma pharmacokinetics of PD-0332991 in children with Rb1positive recurrent, progressive or refractory primary CNS tumors.
SECONDARY OBJECTIVES:
I. To record preliminary evidence of efficacy of PD-0332991 in children with recurrent CNS tumors.
II. To evaluate cyclin-dependent kinase (CDK)4/6, cyclin D1-3, Ink4a-ARF copy-number variations in available tumor tissue by array comparative, genomic hybridization (aCGH).
III. To explore the potential relationships between the pharmacokinetics of PD-0332991 and pharmacodynamic response (e.g. percentage change in absolute neutrophil count [ANC], platelet counts).
IV. To explore the pharmacogenetic polymorphisms in PD-0332991 metabolizing enzymes and transporters and relate these polymorphisms to PD-0332991 pharmacokinetics.
OUTLINE: This is a dose-escalation study.
Patients receive palbociclib isethionate orally (PO) once daily (QD) on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Childrens Hospital Los Angeles
-
Palo Alto, California, United States, 94304
- Lucile Packard Children Hospital Stanford University
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Childrens National Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Lurie Childrens Hospital-Chicago
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children Hospital Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Childrens Hospital
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with retinoblastoma protein (Rb1) positive recurrent, progressive or refractory central nervous system (CNS) tumors
- Histologically confirmed Rb1 positive primary recurrent, progressive, or refractory central nervous system tumors; patients with low grade gliomas are excluded
- Formalin fixed paraffin embedded tumor tissue (preferably from current recurrence) must be available to assess Rb1 protein status prior to enrollment; only patients with recurrent diffuse intrinsic brain stem glioma (DIPG) can be enrolled without the need for available tumor tissue for Rb1 protein status confirmation
- Patients must have measurable disease (in 2-dimensions) on magnetic resonance imaging (MRI) scan of brain and/or spine to assess preliminary evidence of response
Body surface area (BSA):
- Patients enrolled on dose level 1 (50 mg/m^2) must have BSA >= 1.20 m^2
- Patients enrolled on dose level 2 (75 mg/m^2) must have BSA >= 0.93 m^2
- Patients enrolled on dose level 3 (95 mg/m^2) must have BSA >= 0.70 m^2
- Patients must have received no more than 2 prior chemotherapy regimens and/or focal radiotherapy for their brain tumor and fully recovered from the acute treatment related toxicities of all prior therapies prior to entering this study; for those acute baseline adverse events attributable to prior therapy, patients must meet organ function criteria
- Chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study enrollment in the study or at least six (6) weeks for those receiving nitrosourea
- Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
Radiotherapy: patients must have had their last fraction of:
* Focal irradiation > 2 weeks prior to enrollment
- Corticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptoms
- Growth factors: all colony forming growth factor(s) have been discontinued for at least one week prior to enrollment (filgrastim, sargramostim, and erythropoietin); for patients on long acting growth factors, the interval should be two weeks
- Patients with neurological deficits that are stable for a minimum of one week prior to registration
- Patients must be able to swallow capsules
- Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 60
- Absolute neutrophil count >= 1,000/mm^3
- Platelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)
- Hemoglobin >= 8 g/dl
- Total bilirubin =< 1.5 times upper limit of institutional normal (ULN) for age
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal for age
- Serum albumin >= 3 g/dL
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:
- 1 to < 2 years: 0.6 (male), 0.6 (female)
- 2 to < 6 years: 0.8 (male), 0.8 (female)
- 6 to < 10 years: 1 (male), 1 (female)
- 10 to < 13 years: 1.2 (male), 1.2 (female)
- 13 to < 16 years: 1.5 (male), 1.4 (female)
- >= 16 years: 1.7 (male), 1.4 (female)
- Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
- Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control while being treated on this study
- Patient and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines
Exclusion Criteria:
- Patients with any clinical significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that is likely to interfere with the study procedures or results
- Patients with low grade gliomas and Rb1 negative tumors
Patients who have received any of the following:
- > 2 chemotherapy regimens
- Myeloablative chemotherapy with stem cell rescue
- Craniospinal irradiation
- Patients with corrected QT (QTc) interval of > 450 msec or those on medications known to prolong QTc interval
- Prior treatment on a CDK inhibitor
- Patients who are receiving drugs that are strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
- Patients who are receiving any other investigational therapy
- Patients who require enzyme inducing anti-convulsants to control seizures
- Patients with cataracts on ophthalmologic examination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (palbociclib isethionate)
Patients receive palbociclib isethionate PO QD on days 1-21.
Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I
Time Frame: 4 weeks
|
Rolling-6 design was used to estimate MTD.
The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a dose-limiting toxicity (DLT) and the next higher dose level had been determined to be too toxic.
Stratum I consisted of less-heavily pre-treated patients.
|
4 weeks
|
Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II
Time Frame: 4 weeks
|
Rolling-6 design was used to estimate MTD.
The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a DLT and the next higher dose level had been determined to be too toxic.
Stratum II consisted of heavily pre-treated patients.
|
4 weeks
|
Number of Patients Who Experienced Dose Limiting Toxicities (DLTs)
Time Frame: 4 weeks
|
DLTs were defined as any of the following adverse events that were at least possibly related to palbociclib that occurred during the first 4 weeks of therapy regardless of expectedness.
Hematologic DLTs included grade 3 neutropenia with fever and sepsis, grade 3 thrombocytopenia and/or requiring a platelet transfusion on 2 separate days within a 7-day period, or any grade 4 hematologic toxicity except lymphopenia.
Non-hematologic DLTs included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., nausea and vomiting of < 5 days; diarrhea and/or electrolyte disturbances which have not been maximally treated; AST/ALT elevation that returns to levels meeting eligibility criteria within 7 days of study drug interruption and does not recur upon restarting drug), or any grade 2 non-hematologic toxicity that persists for > 7 days and is considered medically significant or sufficiently intolerable by patients requires treatment interruption.
|
4 weeks
|
Single Dose Apparent Volume of Central Compartment (Vc/F)
Time Frame: Up to day 3
|
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib.
Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
|
Up to day 3
|
Single Dose Elimination Rate Constant (Ke)
Time Frame: Up to day 3
|
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib.
Elimination rate constant (Ke) was estimated using a non-compartmental method.
|
Up to day 3
|
Single Dose Half-life (t1/2)
Time Frame: Up to day 3
|
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib.
Half-life (t1/2) was estimated using a non-compartmental method.
|
Up to day 3
|
Single Dose Apparent Oral Clearance (CL/F)
Time Frame: Up to day 3
|
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib.
Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
|
Up to day 3
|
Single Dose Area Under the Plasma Concentration Time Curve (AUC)
Time Frame: Up to day 3
|
On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib.
Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.
|
Up to day 3
|
Steady State Apparent Volume of Central Compartment (Vc/F)
Time Frame: Up to day 22
|
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose.
Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
|
Up to day 22
|
Steady State Elimination Rate Constant (Ke)
Time Frame: Up to day 22
|
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose.
Elimination rate constant (Ke) was estimated using a non-compartmental method.
|
Up to day 22
|
Steady State Half-life (t1/2)
Time Frame: Up to day 22
|
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose.
Half-life (t1/2) was estimated using a non-compartmental method.
|
Up to day 22
|
Steady State Apparent Oral Clearance (CL/F)
Time Frame: Up to day 22
|
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose.
Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
|
Up to day 22
|
Steady State Area Under the Plasma Concentration Time Curve (AUC)
Time Frame: Up to day 22
|
On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose.
Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.
|
Up to day 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Objective Responses
Time Frame: Up to 2 years
|
Objective responses included complete response (CR) and partial response (PR).
|
Up to 2 years
|
Association Between Neutropenia and Single Dose Palbociclib AUC
Time Frame: Up to approximately 4 weeks
|
Neutrophil count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis.
Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between neutrophil count decreased and single dose palbociclib AUC for all participants was examined.
|
Up to approximately 4 weeks
|
Association Between Lymphopenia and Single Dose Palbociclib AUC
Time Frame: Up to approximately 4 weeks
|
Lymphocyte count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis.
Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between Lymphocyte count decreased and single dose palbociclib AUC for all participants was examined.
|
Up to approximately 4 weeks
|
Association Between Leukopenia and Single Dose Palbociclib AUC
Time Frame: Up to approximately 4 weeks
|
White blood cell count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis.
Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between white blood cell count decreased and single dose palbociclib AUC for all participants was examined.
|
Up to approximately 4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Cyclin-dependent Kinase-4 (CDK4) Copy Number Variations
Time Frame: At enrollment
|
CDK4 is a key component in signaling pathways inside normal cells and cancer cells.
CDK4 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Number of Subjects With Cyclin-dependent Kinase-6 (CDK6) Copy Number Variations
Time Frame: At enrollment
|
CDK6 is a key component in signaling pathways inside normal cells and cancer cells.
CDK6 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Number of Subjects With Cyclin D1 Copy Number Variations
Time Frame: At enrollment
|
Cyclin D1 is a key component in signaling pathways inside normal cells and cancer cells.
Cyclin D1 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Number of Subjects With Cyclin D2 Copy Number Variations
Time Frame: At enrollment
|
Cyclin D2 is a key component in signaling pathways inside normal cells and cancer cells.
Cyclin D2 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Number of Subjects With Cyclin D3 Copy Number Variations
Time Frame: At enrollment
|
Cyclin D3 is a key component in signaling pathways inside normal cells and cancer cells.
Cyclin D3 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Number of Subjects With Ink4a-ARF Loss Copy Number Variations
Time Frame: At enrollment
|
Ink4a-ARF is a key component in signaling pathways inside normal cells and cancer cells.
Ink4a-ARF loss copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
|
At enrollment
|
Polymorphisms in Efflux-transporter Proteins P-glycoprotein (P-gp; ABCB1)
Time Frame: At enrollment
|
Polymorphisms in ABCB1 encode for efflux-transporter proteins P-glycoprotein (P-gp), for which palbociclib has been shown as a substrate.
Genomic DNA was to be isolated from peripheral blood samples from consenting patients to determine ABCB1 polymorphisms.
|
At enrollment
|
Polymorphisms in Breast Cancer Resistance Protein (BCRP; ABCG2)
Time Frame: At enrollment
|
Polymorphisms in ABCG2 encode for BCRP, for which palbociclib has been shown as a substrate.
Genomic DNA was to be isolated from peripheral blood samples from consenting patients to determine ABCG2 polymorphisms.
|
At enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Van Mater, MD, Pediatric Brain Tumor Consortium
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Glioma
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Brain Neoplasms
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Cerebral Ventricle Neoplasms
- Neoplasms
- Glioblastoma
- Recurrence
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Medulloblastoma
- Astrocytoma
- Gliosarcoma
- Oligodendroglioma
- Meningioma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Pinealoma
- Neoplasms, Neuroepithelial
- Choroid Plexus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Palbociclib
Other Study ID Numbers
- PBTC-042
- U01CA081457 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Childhood Medulloblastoma
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood... and other conditionsUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States